Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 15,395

Document Document Title
WO/2022/147694A1
Provided herein are novel compounds (e.g., Formula I, II, III, or IV), pharmaceutical compositions, and methods of using the same. The compounds herein can typically induce UCP-1 expression and/or browning of white adipose tissues. The c...  
WO/2022/148331A1
Provided herein are novel compounds (e.g., Formula I, II, III, or IV), pharmaceutical compositions, and methods of using the same. The compounds herein can typically induce UCP-1 expression and/or browning of white adipose tissues. The c...  
WO/2022/142731A1
Disclosed are an antiviral compound and a preparation method therefor. The structural formula of the compound is as represented by formula I. In formula (I), R1 is selected from: monosubstituted or polysubstituted H, F, methyl, and trifl...  
WO/2022/142727A1
Disclosed are an antiviral compound and method for preparation thereof. The structural formula of the compound is as shown in formula I; in formula (I), R 1 is selected from monosubstituted or polysubstituted H, F, methyl, and trifluorom...  
WO/2022/146086A1
The present invention relates to: a compound that is sensitive to γ-hydroxybutyric acid (GHB)-based compounds, and thus changes color; and an application thereof, and since the GHB-based compound-sensitive chromogenic compound of the pr...  
WO/2022/140520A1
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...  
WO/2022/138944A1
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...  
WO/2022/135355A1
Provided is a method for catalytically activating carbon dioxide as a carbonylation reagent with inorganic sulfur. In the method, carbon dioxide can be used to replace a toxic and harmful carbonylation reagent in the presence of H2S and ...  
WO/2022/135613A1
Disclosed in the present invention are a guanidinothiazole compound, and a preparation method therefor and the use thereof. The structural formula of the guanidinothiazole compound is as shown in formula (IV). According to the present in...  
WO/2022/127654A1
An anti-fibrosis pharmaceutical composition and an application thereof. The anti-fibrosis pharmaceutical composition specifically comprises: (a) an NRP1 inhibitor and/or a HIF2α inhibitor; and (b) an EPCR pathway activator that promotes...  
WO/2022/127923A1
The present invention relates to a benzene ring compound and a use thereof. In particular, provided is a compound as shown in formula I, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acce...  
WO/2022/129925A1
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.  
WO/2022/129047A2
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...  
WO/2022/122975A1
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition c...  
WO/2022/125636A1
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...  
WO/2022/124148A1
Provided is a compound which is suited to nucleic acid detection or viscosity measurement. The disclosed compound is equipped with a donor and three acceptors which are bonded to said donor so as to be capable of rotating around said don...  
WO/2022/112188A1
The present invention provides novel compounds having the general formula: (I) wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2022/111605A1
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...  
WO/2022/110916A1
A method for preparing a nitrogen-containing heterocyclic compound and a derivative thereof by means of an enzymatic-chemical cascade method, comprising: reacting an alcohol, an amine, an alcohol dehydrogenase, a flavin molecule and a co...  
WO/2022/105644A1
Provided in the present invention are a salt of a benzothiazole compound as represented by formula I, and a crystal form and the use thereof. The salt is selected from pamoate and palmitate. Further provided is the use of the salt of the...  
WO/2022/108377A1
The present invention relates to a novel compound having inhibitory activity against O-GlcNAcase and a use thereof.  
WO/2022/109148A1
The present disclosure relates generally to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-...  
WO/2022/100634A1
Provided are an organic electroluminescent device and a display apparatus comprising same. The organic electroluminescent device comprises a substrate, an anode electrode, a hole injection layer, a hole transport layer, a light-emitting ...  
WO/2022/103960A1
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...  
WO/2022/095569A1
Disclosed are a heterocyclic compound for an immune checkpoint inhibitor capable of blocking a VISTA signaling pathway, and a preparation method therefor and a use thereof. The compound is as represented by formula I. The compound has a ...  
WO/2022/090409A1
The invention relates to novel deuterated compounds of Formula (I) to a process for their preparation and to their use as medicament, in particular as antiviral medicament.  
WO/2022/083703A1
This disclosure relates to LPA antagonists of Formula (I) : including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.  
WO/2022/079290A2
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...  
WO/2022/076628A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...  
WO/2022/076403A1
This disclosure provides compounds for the treatment of medical disorders such as cancer, and more particularly compounds which find use as inhibitors of CMG helicase.  
WO/2022/076629A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis usi...  
WO/2022/069462A1
The present invention relates to a process for the preparation 2-chloro-1-(2-chlorothiazol-5-yl)ethanone.  
WO/2022/063153A1
Provided are compounds of Formula (I) or (II) and related compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).  
WO/2022/063152A1
Provided are compounds of Formula I, compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).  
WO/2022/058733A1
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...  
WO/2022/057387A1
A 3-(3-Aryl/heteroaryl-4-thiazolinone)-N-aryl/heterocyclic benzamide compound, or a pharmaceutically-acceptable salt thereof, and a preparation method therefor. The compound type or a pharmaceutical composition thereof can be used to tre...  
WO/2022/057223A1
A benzothiazole meroterpenoid compound derived from deep sea fungi and a derivative thereof, and a preparation method therefor and the use thereof in the preparation of an anti-tumor drug. The benzothiazole meroterpenoid compound is a co...  
WO/2022/059028A1
The present invention relates to a novel crystalline polymorph of Sodium (2R,5S,13aR)-7,9-dioxo-10-[(2,4,6-trifluorobenzyl)carbamoyl] -2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]py razino[2,1-b][1,3]oxazepin-8-olate (Bicteg...  
WO/2022/053660A2
The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X1 being S or O, X2 being S or O and at least one of X1 and X2 being S R2 H or C1-4-alkyl, R3 H or C1-4-alkyl R6 and R7 are hydrogen ...  
WO/2022/056447A1
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.  
WO/2022/049376A1
The invention relates to compounds of formula (I): and related aspects.  
WO/2022/051286A1
The present disclosure includes compounds, compositions, and methods for preventing or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise ...  
WO/2022/051565A1
The invention provides substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disor...  
WO/2022/047014A1
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...  
WO/2022/043322A1
The present invention relates to compounds of formula (la) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. Formula (la). These compounds are useful in the treatment of bacterial infections, especially caused by ...  
WO/2022/040747A1
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...  
WO/2022/045618A1
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...  
WO/2022/037927A1
New isobutyramides.  
WO/2022/038356A1
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...  
WO/2022/040324A1
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).  

Matches 201 - 250 out of 15,395